Pharma Rewires Drug Development With AI Operations
Drug development has grown too expensive and too slow to rely on manual workflows, as the cost of bringing a single therapy to market climbs into the billions and approval timelines stretch across a d...
Copyright Kills Competition
Copyright owners increasingly claim more draconian copyright law and policy will fight back against big tech companies. In reality, copyright gives the most powerful companies even more control over c...
Blue Owl Eyes New Deals as It Pushes Deeper Into AI Boom
If there are growing worries about the scale of money pouring into AI, word of that hasn’t reached Marc Lipschultz. He is co-CEO of Blue Owl Capital, a publicly traded investment firm that has struc...